AstraZeneca Pharmaceuticals LP
About AstraZeneca Pharmaceuticals LP
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
YEAR FOUNDED:
1999
LEADERSHIP:
CEO: Pascal Soriot
CFO: Marc Dunoyer
CMO: Marc Dunoyer
CTO: Andrew Chen
CCO: Katarina Ageborg
CMO: Sean Bohen
CLINICAL TRIAL:
Please click here for clinical trial information.
JOB OPPORTUNITY:
Please click here for AstraZeneca job opportunities.
PRODUCTS:
AstraZeneca Medications
For more information, visit
www.astrazeneca.com and follow us on www.twitter.com/astrazeneca.
FOLLOW AstraZeneca:
Tweets by AstraZeneca
What Science Can Do
2059 articles with AstraZeneca Pharmaceuticals LP
-
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
-
During an interim analysis of ELEVATE-TN data, AstraZeneca said Calquence met primary endpoints in patients with previously untreated CLL.
-
ASCO called rare cancer treatments the "advance of the year" in oncology.
-
AstraZeneca underwent a restructuring earlier this year with an increased focus on oncology.
-
Companies share robust oncology data at annual ASCO meeting.
-
Olivier Nataf, head of AstraZeneca’s U.S. oncology business unit, is excited about the potential the company’s PARP inhibitor Lynparza is showing as a potential treatment of pancreatic cancer.
-
With ASCO set to kick off on Friday, companies prepare to share data from multiple cancer treatment pipeline programs.
-
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
-
The triple combination therapy does not use a chemotherapy agent in its experimental treatment for an aggressive blood cancer.
-
Boston and its surrounding communities, particularly the community of Cambridge, have become the hottest biotech hotspot on the East Coast of the United States.
-
The primary endpoint was objective response rate (ORR). Secondary objectives included duration of response, disease control rate, clinical benefit rate, progression-free survival and overall survival.
-
Full data will be shared at a later conference, but the study marked the first time a BTK inhibitor showed benefit as a monotherapy in CLL.
-
AstraZeneca announced a long-term collaboration deal with BenevolentAI, a UK-based company focused on combining computational medicine and advanced artificial intelligence.This deal only marks one of the most recent AI team-ups announced in the biopharma industry.
-
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
-
AstraZeneca reported first-quarter financials, with Product Sales growing 10% (14% at CER) to $5.465 billion. What is more startling, and completely in accordance with the company’s stated goals, Global Oncology sales increased by 54%.
-
AstraZeneca signed a global development and commercialization deal with Daiichi Sankyo Company for trastuzumab deruxtecan (DS-8201).
-
The rumors speculated that AstraZeneca planned to acquire Aveo in the second quarter of this year in order to gain the company's kidney cancer drug, Tivozanib.
-
One year after spinning out from AstraZeneca’s MedImmune, Viela Bio is already anticipating filing a Biologics License Application with the U.S. Food and Drug Administration for its lead asset, inebilizumab.
-
March is National Kidney Month, with March 14 designated as World Kidney Day. The kidneys are called the body’s chemical factories. Their job is to filter waste and perform specific important jobs like controlling red blood cell production and blood pressure.
-
A new market research report by Clarivate Analytics, “Cortellis Drugs to Watch,” identified seven new drugs it believes will hit sales of $1 billion or more, the so-called “blockbuster” mark, by 2023.